Introduction
============

Precursor B-cell acute lymphoblastic leukemia (B-ALL) is a heterogeneous disease characterized by a variety of genetic abnormalities.^[@b1-1040128]^ In approximately one-quarter of B-ALL patients, known as the B-other-subgroup, the known major risk-stratifying cytogenetic abnormalities are absent.^[@b2-1040128]^ However, recent studies using advanced analytical approaches have described a range of novel genetic subgroups among B-other-ALL.^[@b3-1040128]--[@b11-1040128]^

The *myocyte enhancer factor 2D* (*MEF2D*) gene, located at 1q22, is present among these newly identified rearrangements in B-other-ALL.^[@b6-1040128],[@b7-1040128],[@b10-1040128],[@b12-1040128]--[@b14-1040128]^ Seven known fusion partners: *B-cell CLL/lymphoma 9* (*BCL9*, 1q21), *heterogeneous nuclear ribonucleoprotein U-like 1* (*HNRNPUL1*, 19q13.2), *deleted in azoospermia-associated protein* 1 (*DAZAP1*, 19p13.3), *colony stimulating factor 1 receptor* (*CSF1R*, 5q32), *synovial sarcoma translocation, chromosome 18* (*SS18*, 18q11.2), *signal transducer and activator of transcription 6* (*STAT6*, 12q13.3), and *Forkhead Box J2* (*FOXJ2*, 12p13.31) have been described, mostly among childhood and young adult B-ALL. The *MEF2D* gene encodes a member of the transcription factor family involved in the control of muscle and neuronal cell differentiation and development, which is regulated by class II histone deacetylases.^[@b15-1040128]--[@b17-1040128]^ It has been reported that rearrangements result in enhanced *MEF2D* transcriptional activity and lymphoid transformation, thus contributing to the development of a distinct subtype of high-risk leukemia.^[@b7-1040128],[@b10-1040128]^ However, the true incidence and clinical characteristics, including outcome, of patients with B-ALL harboring *MEF2D* fusion genes remains unknown.

In this study, we report the detailed analysis of a subgroup of B-ALL with *MEF2D* fusions within a Japanese pediatric ALL cohort. The *heterogeneous nuclear ribonucleoprotein H1* gene (*HNRNPH1*), encoding another family member of heterogeneous nuclear ribonucleoprotein,^[@b18-1040128]^ was identified as a new fusion partner of the *MEF2D* gene. Novel immunophenotypic characteristics and accompanying genetic abnormalities as well as distinctive clinical features of B-ALL harboring *MEF2D* fusions are evaluated and discussed.

Methods
=======

Patient selection and sample preparation
----------------------------------------

RNA and DNA samples, obtained from pediatric B-ALL patients and stored in the Tokyo Children's Cancer Study Group (TCCSG) biobank^[@b5-1040128],[@b11-1040128]^ were used in this study (*Online Supplementary Figure S1, Table S1*). As indicated in *Online Supplementary Table S1*, the majority of cases originated from the TCCSG L04-16 study^[@b19-1040128]^ while others, including 2 B-lymphoblastic lymphoma (LBL) patients, originated from different cohorts. All investigations were approved by the institutional review boards and informed consent or assent was obtained from parents or guardians based on their age and level of understanding, as described previously.^[@b5-1040128],[@b11-1040128]^ *Online Supplementary Figure S1* shows the analysis carried out on each case.

Total RNA and genomic DNA were extracted from bone marrow or peripheral blood of patients using the miRNeasy Mini Kit and the QIAamp DNA Mini Kit (Qiagen, Inc., Valencia, CA, USA), respectively.

In this paper, B-other-ALL is defined as B-ALL lacking the major risk stratifying genetic abnormalities, including high hyperdiploidy (≥ 51 chromosomes or DNA index ≥ 1.16), low hypodiploidy/near haploidy (≤ 44 chromosomes), fusions of *ETV6-RUNX1, TCF3-PBX1, TCF3-HLF, BCR-ABL1*, and *MLL* rearrangements as well as more recently identified genetic abnormalities, including rearrangements of *CRLF2* and *ZNF384*, Ph-like ALL-related tyrosine kinase fusions as well as *MEF2D* fusions (*Online Supplementary Table S1*).

Whole transcriptome sequencing and RT-PCR
-----------------------------------------

From previous whole transcriptome sequencing (WTS) of B-other-ALL, we identified cases with *ZNF384* fusions^[@b11-1040128]^ as well as other abnormalities (*Online Supplementary Figure S1, Table S1*).^[@b19-1040128]--[@b21-1040128]^ We re-analyzed remaining 153 WTS data manipulated by "deFuse",^[@b22-1040128]^ an algorithm for gene fusion discovery, and investigated the presence of *MEF2D* fusions. Details of this data analysis have been described previously.^[@b11-1040128]^ RT-PCR followed by Sanger sequencing was performed to confirm and screen for fusion transcripts, as described previously,^[@b5-1040128],[@b11-1040128]^ using the primers listed in *Online Supplementary Table S2*.

Multiplex Ligation-dependent Probe Amplification (MLPA)
-------------------------------------------------------

MLPA analyses were performed on genomic DNA using two types of SALSA Reference Kits, P335 and P383 (MRC Holland, Amsterdam, the Netherlands), according to the manufacturer's instructions. After separation of amplified products, using the ABI3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), the results were analyzed using Gene Mapper Software (Applied Biosystems) and data, including informative headers, electropherograms, ratio plots, validation boxes, and report tables were obtained. In this study, we present only results of deletions of the exons targeted in these kits.

Whole exome sequencing (WES)
----------------------------

Exome libraries prepared from 100 ng of genomic DNA were sequenced using SBS v.4 reagents with the HiSeq2500 sequencing system. Details of whole exome data analyses have been described previously.^[@b11-1040128]^

Microarray and data analyses
----------------------------

The gene expression signature for *MEF2D* fusion-positive BALL was investigated by DNA microarray-based expression profiling using Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA). Data were normalized and filtered as described previously.^[@b11-1040128]^ Further details are provided in *Online Supplementary Methods*.

Statistical analysis
--------------------

Mutual univariate analyses of characteristics were conducted using Fisher's exact test or the c^2^ test for qualitative variables. Overall survival (OS) and event-free survival (EFS) were estimated by the Kaplan-Meier method and compared by the log-rank test. Analyses were performed using Prism software, version 6.0 (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

Detection of *MEF2D* fusions in pediatric B-ALL patients
--------------------------------------------------------

Among the 328 selected RNA samples from B-ALL patients (*Online Supplementary Figure S1*) analyzed by WTS and/or RT-PCR followed by Sanger sequencing, we identified 9 and 6 patients with *MEF2D-BCL9* and *MEF2D-HNRNPUL1*, respectively ([Table 1](#t1-1040128){ref-type="table"}, *Online Supplementary Table S1 and S3*, [Figure 1](#f1-1040128){ref-type="fig"} and Online Supplementary Figure S1). Of note, one case of each abnormality was identified by gene expression profiling (details in *Online Supplementary Information*). We also identified an additional case with *MEF2D-BCL9* ([Table 1](#t1-1040128){ref-type="table"}, Case 10) in B-LBL. As well as the known *MEF2D* fusions, we identified *MEF2D-HNRNPH1* as a novel fusion in 1 patient ([Figure 1](#f1-1040128){ref-type="fig"}, [Table 1](#t1-1040128){ref-type="table"}, Case 17). Among the L04-16/L06-16 cohort,^[@b11-1040128],[@b19-1040128]^ comprising a consecutive series of 290 B-ALL patients, including 126 classified as B-other-ALL, 5 *MEF2D-BCL9* and 2 *MEF2D-HNRNPUL1* patients were identified (*Online Supplementary Table S1 and Figure S1*). The incidence of *MEF2D* fusions in childhood ALL, calculated from this cohort, was 5.6% in B-other-ALL and 2.4% in B-ALL overall. *MEF2D-BCL9* was the most recurrent, at a frequency of 4.0% in B-other-ALL and 1.7% in B-ALL overall.

###### 

Characteristics of *MEF2D* fusion-positive cases.
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![Structures of the *MEF2D* fusions. Structures of fusion proteins and nucleotide sequences of (a) - (e) *MEF2D-BCL9*, (f) *MEF2D-HNRNPUL1*, (g) and (h) *MEF2D-HNRNPH1*. The red arrowhead shows the donor and acceptor site breakpoint. The number of patients in whom a particular fusion isoform was found is indicated on the right.](104128.fig1){#f1-1040128}

Structure of *MEF2D* fusions
----------------------------

The structure and sequences of *MEF2D-BCL9* as well as a schematic representation of the predicted fusion proteins, are depicted in [Figure 1](#f1-1040128){ref-type="fig"}, [Table 1](#t1-1040128){ref-type="table"} and *Online Supplementary Table S3*. Five isoforms of *MEF2D-BCL9* fusion were identified in 10 patients, including one case in which different isoforms were present together. Most frequently, exon 6 of *MEF2D* was fused in-frame to exon 10 of *BCL9* in 5 patients ([Figure 2A](#f2-1040128){ref-type="fig"}, Type (a)), in accordance with previous reports.10 Exons 5 and 6 of *MEF2D* were also fused to exon 9 of *BCL9* in 4 and 1 patient, respectively (Types (b) and (c)). In addition, we identified two novel breakpoints (Types (d) and (e)). The predicted protein from all fusions retains the DNA-binding MADS domain of the MEF2D protein, while it lacks most of the c-terminal portion of MEF2D as well as most of the functional domains of BCL9.

![Immunophenotypic characteristics of B-ALL patients with *MEF2D* fusions. (A) The positivity (percentage) of CD10, cytoplasmic m, CD5, CD38, and CD33 of *MEF2D* fusion-positive, *TCF3-PBX1*-positive, and B-other patients are plotted as a scattergram. A detailed list of positivity for each immunophenotypic marker of the patients is presented in *Online Supplementary Table S4*. (B) Typical histograms of CD10, CD19, cytoplasmic m, aberrant CD5, CD33, and CD38 of *MEF2D-BCL9, MEF2D-HNRNPUL1, TCF3-PBX1*, and B-other patients are indicated with a positive rate (%). X-axis, fluorescence intensity; Y-axis, relative cell number.](104128.fig2){#f2-1040128}

The structure and sequences of *MEF2D-HNRNPUL1* are also presented in [Figure 1](#f1-1040128){ref-type="fig"}. Distinct from previous reports, only one isoform joining exon 9 of *MEF2D* to exon 12 of *HNPNPUL1* (Type (f)) was observed among our 6 patients. In the case of *MEF2D-HNRNPH1*, two isoforms, in-frame fusions joining exons 4 and 7 of *MEF2D* to exon 5 of *HNPNPH1* (Type (g) and (h)), respectively, were identified in the same patient.

Immunophenotypic characteristics of B-ALL patients with *MEF2D* fusions
-----------------------------------------------------------------------

It has been reported that B-ALL patients with *MEF2D* fusions show dull or negative expression of CD10 and overexpression of CD38 antigens, based on immunophenotypic examination.^[@b10-1040128]^ Among our *MEF2D* fusion-positive cases, CD10 expression was lower than that seen in *TCF3-PBX1*-positive patients, but not B-others-ALL, as shown in [Figure 2](#f2-1040128){ref-type="fig"}, *Online Supplementary Figure S3 and Table S4*. On the other hand, CD38 expression in *MEF2D* fusion-positive cases was higher than B-other-ALL patients, but not *TCF3-PBX1*-positive patients. We also observed that expression of the cytoplasmic m chain was higher in *MEF2D* fusion-positive cases than that in B- other-ALL patients, with more than 10% of blasts positive for cytoplasmic m in 8/12 patients (ranging from 5.50 to 99.74%, mean: 54.14 ± 41.38%). Moreover, B-ALL patients with *MEF2D* fusions frequently exhibited aberrant CD5 expression, with more than 10% of the blasts positive for CD5 in 7/12 patients (ranging from 0.60 to 73.30%, mean: 27.01 ± 26.67%).

Additional genetic abnormalities in *MEF2D* fusion-positive patients
--------------------------------------------------------------------

To elucidate the frequency of additional genetic abnormalities in B-ALL with *MEF2D* fusions, we initially performed MLPA on 16 DNA samples from patients with *MEF2D* fusions. As shown in *Online Supplementary Table S5*, MLPA analysis revealed that deleted or amplified regions of *IKZF1, CRLF2, EBF1, BTG1, PHF6, NF1, EZH2, SUZ12*, or *PTEN* were absent from *MEF2D* fusion-positive cases, although 11/16 exhibited *CDKN2A/CDKN2B* deletions at a frequency significantly higher than that among the B-other-ALL patients enrolled on L04-16/L06-16 study (*P*\<0.001, *data not shown*). Heterozygous deletions of *LEF1, PAX5*, and *ETV6* were detected in 1 case each.

To further investigate the presence of additional genetic abnormalities affecting coding sequences in B-ALL with *MEF2D* fusions, we carried out WES on 3 DNA samples. We identified 16 mutations within genes that had been previously recognized within cancer: *ALK, ARFGER3, BRCA1, BRMS1, C8orf4, ITIH1, MAPK13, NCOR2, NLE, NOTCH1, PHF3, PHF6, PHF10, PIK3R5, RB1*, and *TET1* (*Online Supplementary Table S6*).

As mutations involving *NOTCH1* and *PHF6* are known to be recurrent in T-ALL^[@b23-1040128]--[@b26-1040128]^ and *NLE* encodes the modulator of NOTCH1,^[@b27-1040128]^ we were encouraged to investigate abnormalities in NOTCH1 signaling pathway genes and other genes reported as targets of recurrent genetic abnormalities in T-ALL. Thus, we performed RT-PCR and Sanger sequencing of selected genes, including *FBXW7, NLE, NOTCH1, PHF6*, and *PTEN*, and combined these data with the results of WES. As shown in [Table 2](#t2-1040128){ref-type="table"}, mutations in NOTCH1 signaling pathway genes, including *FBXW7, NLE*, and *NOTCH1*, were detected in 4/16 patients. In addition, 8 and 1 of 16 patients exhibited mutations in *PHF6* and *PTEN*, respectively.

###### 

Additional genetic abnormalities of *MEF2D* fusion-positive cases.
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Gene expression signature of *MEF2D* fusion-positive patients
-------------------------------------------------------------

We have microarray data of B-ALL as indicated in *Online Supplementary Figure S1*,^[@b11-1040128]^ and, in addition, we performed WTS to search for new fusion genes specifically among cases of B-other-ALL. To further assess the functional aspects of *MEF2D* fusions, we performed DNA microarray-based expression profiling. Upon supervised hierarchical clustering analysis using selected gene probe sets (*Online Supplementary Table S7 and S8*), we observed distinct clustering of *MEF2D* fusion cases, with clear separation from cases with other genetic abnormalities, indicating that *MEF2D* fusion cases have a distinct gene expression signature ([Figure 3A](#f3-1040128){ref-type="fig"}). Of note was that this cluster of *MEF2D* fusion cases was close to that of *TCF3-PBX1*-positive cases. Principal component analysis (PCA) also revealed clear clustering of *MEF2D* fusion cases separate from those cases with other genetic abnormalities, but close to the cluster of *TCF3-PBX1*-positive cases ([Figure 3B](#f3-1040128){ref-type="fig"}).

![Characteristics of gene expression profile in *MEF2D*-fusion-positive ALL. (A) Two-way hierarchical clustering and (B) principal component analysis (PCA) were performed on the microarray data, including B-ALLs with *MEF2D* fusion-positive and other types of genetic abnormalities, using the probe sets of differentially expressed genes between B-ALL with *MEF2D* fusions and other types of genetic abnormalities selected from filtered microarray probes (presented in *Online Supplementary Tables S7* and *S8*). The results of clustering analysis are displayed using a heat map as a dendrogram.](104128.fig3){#f3-1040128}

As *TCF3-PBX1*-positive cases also express the cytoplasmic μ chain-positive pre-B ALL immunophenotype,^[@b28-1040128],[@b29-1040128]^ we subsequently compared the gene expression of *MEF2D* fusion cases with *TCF3-PBX1*-positive cases as well as B-other-ALL. As shown in *Online Supplementary Figure S4*, *MEF2D* fusion patients were clearly separate, within a distinct cluster from *TCF3-PBX1*-positive and B-other-ALL cases, based on unsupervised hierarchical clustering. Up-regulated genes common to both *MEF2D* fusion and *TCF3-PBX1*-positive cases compared to B-other-ALL included: *IKZF2, IRF4, TCL6, IGHG, IGHV5-78, IGLL1, VPREB3*, and *BCL2L11*, while *RUNX2, IRF9, CRLF2, CD34*, and *CCND2* were common down-regulated genes (summarized in *Online Supplementary Figure S5*). *HDAC9* was also identified as a common up-regulated gene in both *MEF2D* fusion and *TCF3-PBX1*-positive cases, whereas its expression was significantly higher in *MEF2D* fusion than *TCF3-PBX1*-positive cases. On the other hand, *MEF2D*, *MME* (coding CD10), and *RAG1* were down-regulated in *MEF2D* fusion, but not in *TCF3-PBX1*-positive cases, thus the low-level expression of CD10 seen in *MEF2D* fusion cases was identified at the gene-expression level. Interestingly, *GATA3* was identified as a highly expressed gene in *MEF2D* fusion cases, yet it was significantly down-regulated in *TCF3-PBX1*-positive cases.

To explore the gene expression characteristics of *MEF2D* fusion ALL connected with B-cell differentiation, we performed GSEA using 18 curated gene sets of B lymphocytes at various differentiation stages, as well as 7 early hematopoietic stages including stem cells. Firstly, we compared the gene expression signatures of B-ALL cases with different types of genetic abnormalities. Using B-other-ALL as a reference control, we observed that the majority of gene expression signatures found in B lymphocytes at various differentiation stages were enriched in ALL cases with *TCF3-PBX1* (*Online Supplementary Table S10 and S11*). In contrast, only three gene sets were enriched in *MEF2D* fusion ALL. We further examined the gene expression characteristics of *MEF2D* fusion ALL by direct comparison with *TCF3-PBX1*, and observed that most of the signatures of differentiation stage-specific B lymphocytes as well as early hematopoietic populations were enriched in *TCF3-PBX1*, but not *MEF2D* fusion ALL (*Online Supplementary Table S10*).

Clinical characteristics and outcomes of *MEF2D* fusion-positive patients
-------------------------------------------------------------------------

The clinical findings and outcome of patients with *MEF2D* fusions are summarized in [Table 1](#t1-1040128){ref-type="table"}. *MEF2D* fusion B-ALL patients were aged between 3 and 15 years (median: 9 years) at presentation and comprised 6 males and 10 females. Their initial white blood cell (WBC) counts at presentation ranged from 3,400 to 124,100 (median: 27,300/μl). Analysis of fluids obtained by lumbar puncture revealed no indication of central nervous system (CNS) involvement (data not shown). Among 13 patients, 10 (62.5%) and 4 (25.0%) were classified with an intermediate risk (IR) and high risk (HR), respectively, based on advanced age, elevated WBC counts, or both, and thus standard risk (SR) was assigned to only 2 patients. The response to steroid monotherapy, using the cutoff of 1,000/μL for the blast count in peripheral blood on day 8 was not poor in *MEF2D* fusion patients; however, among 15 patients, 8 (53.3%) showed bone marrow or CNS relapse, and all of the relapsed patients died. As shown in [Figure 4](#f4-1040128){ref-type="fig"}, both the 5-year EFS and OS rates for *MEF2D* fusion patients were significantly lower compared with a consecutive series of B-other-ALL patients enrolled onto the L04-16/L06-16 study (*P*=0.0306 and *P*=0.0013, respectively), indicating that outcomes for *MEF2D* fusion-positive patients were significantly less favorable than those with B-other-ALL.

![Outcomes of patients with *MEF2D* fusions. (A) Kaplan-Meier estimates of event-free survival (EFS) of patients with *MEF2D* fusions, and B-other, log-rank *P*=0.306). (B) Overall survival (OS) for the same as above (log-rank *P*=0.0013).](104128.fig4){#f4-1040128}

Discussion
==========

In this study, we identified *MEF2D* fusions, including a novel fusion gene, *MEF2D-HNRNPH1*, at an incidence of approximately 2% in our B-ALL cohort. It was notable that we identified *MEF2D* fusions in B-LBL. B-ALL patients with *MEF2D* fusions showed unique clinical and biological characteristics. They exhibited an older age at presentation and elevated WBC counts, thus were mostly classified into the IR or HR groups. Although their response to steroid treatment was not poor, *MEF2D* fusion patients showed a significantly worse prognosis with more than half of them relapsing and dying within 1 year. It is noteworthy that stem cell transplantation was not effective in any of the five cases where it was administered as a salvage therapy for relapsed patients in our cohort. Therefore, the establishment of an early diagnostic method and a new therapeutic strategy are necessary for this type of B-ALL. As *ex vivo* sensitivity of xenografted leukemic cells harboring *MEF2D* fusions to HDAC inhibitors has been recently reported,^[@b10-1040128]^ it may offer a plausible therapeutic option for this type of BALL. In relation to diagnosis, we have already established a qPCR based detection assay for the frequent *MEF2D* fusions, which may be useful for rapid diagnosis in combination with FISH.

Another interesting observation is that B-ALL cases with *MEF2D* fusions have a characteristic immunophenotype, most typically presenting as CD5- and cytoplasmic μ chain-positive. Although it was previously reported that their immunophenotypes were characterized by weak or absent expression of CD10 and high expression of CD38,^[@b10-1040128]^ we found that CD10 expression was not significantly lower than B-other-ALL, and that CD38 expression level was similar to that of *TCF3-PBX1*-positive cases. Therefore, B-ALL patients with *MEF2D* fusions could be more effectively diagnosed by combining genetic testing with immunophenotyping.

As shown in [Table 1](#t1-1040128){ref-type="table"}, *MEF2D* fusion cases were mutually exclusive of the known risk stratifying chromosomal translocations, at least at the cytogenetic level. Among additional genetic alterations in *MEF2D* fusion cases, we identified a significantly higher frequency of *CDKN2A/CDKN2B* deletions. At initial diagnosis, 7/8 (87.5%) relapsed patients had *CDKN2A/CDKN2B* deletions, while they were seen in only 2/7 (28.6%) non-relapse patients. Thus, the prognostic impact of *CDKN2A/CDKN2B* deletions in *MEF2D* fusion B-ALL needs to be assessed in larger patient cohorts. Interestingly, we also identified that *MEF2D* fusion patients had mutations in genes known to be recurrent in T-ALL; in particular, there was an unexpectedly high frequency of mutations in *PHF6* (8/16). *PHF6* encodes a plant home-odomain (PHD) factor with a proposed role in gene expression control.^[@b30-1040128]^ As *PHF6* has been proposed to play a role as a tumor suppressor gene,^[@b24-1040128]^ it may participate in the pathogenesis of *MEF2D* fusion B-ALL. Thus, further investigation is needed to clarify this role. Additionally, mutations of genes in the RAS pathway (*NRAS, KRAS, NF1*, and *PTPN11*) or *IKZF1* alterations were not observed in our cases, in conflict with previous reports.

Our data also showed that *MEF2D* fusion B-ALL has a gene expression signature significantly distinct from other genetic subtypes of B-ALL. Supervised analysis led to separation of *MEF2D* fusion cases into isolated clusters both in PCA and hierarchical clustering, and these clusters were the closest neighbors to *TCF3-PBX1*-positive cases. This observation is consistent with the knowledge that both types of B-ALL tend to show a pre-B ALL immunophenotype, and high-level expression of pre-BCR components, including *IGHG/IGHV5-78* and *IGLL1*, were commonly observed in both subtypes.^[@b31-1040128]^ However, when we examined the gene expression signatures closely, there were significant differences between them.

It has recently been shown that MEF2 family proteins, including MEF2C and MEF2D, play a critical role in early B-cell differentiation. It was demonstrated that B-cell development was blocked at the pre-B-cell stage in *Mef2c/d*-deficient mice, indicating that they are essential for progression of B-cell precursors (large to small pre-B-cell transition).^[@b32-1040128]^ It was further shown that, upon activation *via* pre-B-cell receptor signaling, Mef2c/d induces target genes, including *interferon regulatory factor 4* (*Irf4*; stimulates the expression of *Ikzf1/3*) and *histone deacetylase 5/9* (*Hdac5/9*; encoding the protein known to repress Mef2c activity) as we have summarized schematically in *Online Supplementary Figure S4*. On the other hand, *MEF2D* fusion B-ALL cases exhibited elevated expression of *IRF4* and *HDAC9* with down-regulation of *MEF2C*, although it has been suggested that deregulated expression of the N terminus of MEF2D should induce the up-regulation of the target genes of MEF2C/D, whereas subsequent excess of HDAC9 activity represses MEF2C and its downstream gene expression cascade.^[@b10-1040128]^

Our existing data further revealed that up-regulation of *GATA3* is another gene expression characteristic of *MEF2D* fusion ALL. GATA3 is a critical transcription factor in early T-cell development^[@b33-1040128]--[@b35-1040128]^ and its transcriptional repression is essential for early B-cell commitment,^[@b36-1040128]--[@b37-1040128]^ while it has also been reported that GATA3 exhibits myeloid-inducing activity in committed B-lymphocytes under the defect of PAX5 function.^[@b38-1040128]--[@b41-1040128]^ Furthermore, significantly increased *GATA3* mRNA levels were associated with *ZNF384* fusion-positive cases and a higher risk of relapse in childhood B-ALL with the Ph-like phenotype.^[@b42-1040128]--[@b43-1040128]^ As our data also indicated down-regulation of *GATA3* expression in *TCF3-PBX1*-positive cases, ectopic overexpression of *GATA3* appears to participate in establishment of a characteristic gene expression signature as well as the biological signature of *MEF2D* fusion ALL distinct from that of other genetic subtypes of B-ALL.

The roles of the *MEF2D* fusion partners in terms of their biological effects within the fusion molecules of *MEF2D* fusion ALL are largely unknown. The genes known to be fused to *MEF2D* in B-ALL have a variety of biological functions. For example, BCL9 is known to be related to WNT/β-catenin signaling, whereas the *MEF2D-BCL9* fusion retains only the last one or two exons of the *BCL9* gene, thus lacking the functional domains required for WNT/β-catenin signaling, suggesting a role other than deregulation of WNT/β-catenin signaling.^[@b10-1040128]^ *HNRNPUL1* encodes a nuclear RNA-binding protein of the heterogeneous nuclear ribonucleoprotein family that may play a role in nucleocytoplasmic RNA transport and DNA repair,^[@b18-1040128]^ whereas its role as a portion of the fusion molecule in the pathogenesis of B-ALL remains unclear. As HNRNPH1 is a member of the same protein family as HNRNPUL1, both MEF2D-NRNPUL1 and MEF2D-HNRNPH1 likely share the same unknown function.

In conclusion, we have shown that ALL patients harboring *MEF2D* fusion genes possess a characteristic immunophenotype and gene expression signature as well as distinct clinical features, defining them as a distinct genetic subtype among B-other-ALL. Although additional studies are required to elucidate the biological function of the MEF2D fusion protein in leukemogenesis, our data has allowed improved characterization of this new B-ALL subtype.
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